Haleon Reports Sales Lift From Products Marketed to GLP-1 Drug Users

Haleon (NYSE: HLN) said a U.S. retail strategy aimed at consumers taking GLP-1 weight-loss medications produced an average 24% increase in sales per store during the first quarter when its products were displayed both in standard aisles and dedicated GLP-1 sections.

The consumer health company, which makes Advil pain relievers, TUMS indigestion tablets and Biotène oral-care products, has been working with U.S. retailers including CVS Pharmacy (NYSE: CVS) to place over-the-counter products near merchandise intended for people using GLP-1 medications.

GLP-1 drugs such as Novo Nordisk’s (NYSE: NVO) Wegovy and Eli Lilly’s (NYSE: LLY) Zepbound and Foundayo are used for weight loss by mimicking a hormone that helps people feel full. Reported side effects can include nausea, vomiting, constipation, diarrhea, abdominal pain and stomach cramps. According to Haleon, its brands account for most of the space allocated to GLP-1-related products at CVS. The company also said items placed in dedicated GLP-1 sections are selling better than the same products at stores without those displays.

CVS said it has expanded its assortment of both CVS-branded and national-brand over-the-counter products intended to help consumers manage potential side effects. The retailer did not directly address Haleon’s statements about its shelf presence or sales performance.

About 11% of Americans are taking GLP-1 weight-loss drugs, according to analytics company Gallup. Haleon has also discussed its GLP-1 retail strategy with Walmart and Target, according to the company spokesperson. 

About Haleon

Haleon (NYSE: HLN) is a consumer health company headquartered in the United Kingdom and listed in London. Its portfolio includes over-the-counter medicines, oral-health products and other consumer health brands.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.